Please visit our MS learning channel on Youtube, providing you with hundreds of our education programs, filled with ms related topics that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

==================================

Sunday, January 6, 2013

Rebif®, Rebidose - auto-injector, approved


Rebif Single-Use Auto-Injector Approved


Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif®, has been approved by the U.S. Food and Drug administration for the treatment of relapsing forms of MS, according to EMD Serono.

A statement issued by the company said that it anticipates making the product available in a monthly pack in 22 micrograms and 44 micrograms, and in a titration pack. It is expected to be available in theUSin early 2013.

Approval was based on a 12-week phase IIIb multicenter, open-label, single-group study looking at ease of use, patient satisfaction and acceptability, and functional reliability, according to the statement. The 109 participants, aged 18 to 65 years, had relapsing MS meeting McDonald criteria and had already been treated consistently with 44 micrograms, three times weekly, for 12 weeks or more before screening. Patients then completed a user trial questionnaire at weeks six and 12.

The primary endpoint was the proportion of participants rating the auto-injector as "easy to use" or "very easy to use" at week 12. Safety evaluation included the incidence of serious adverse events. Results showed that "the majority of patients found the device easy to use," the statement notes.

With this approval, there are now three delivery options for Rebif: prefilled syringes, Rebiject II, and Rebif Rebidose. Users should demonstrate competency in all aspects of the injection before independent use, and people with severe neurologic deficits should not self-administer injections without assistance from a trained caregiver.



..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

No comments: